{"id":"empirical-vancomycin","safety":{"commonSideEffects":[{"rate":"5-10%","effect":"Nephrotoxicity"},{"rate":"1-5%","effect":"Ototoxicity"},{"rate":"10-15%","effect":"Red man syndrome (flushing, pruritus)"},{"rate":"5-10%","effect":"Phlebitis at infusion site"},{"rate":"5%","effect":"Fever"},{"rate":"1-3%","effect":"Thrombocytopenia"}]},"_chembl":{"chemblId":"CHEMBL262777","moleculeType":"Small molecule","molecularWeight":"1449.27"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Vancomycin works by preventing cross-linking of peptidoglycan strands in the bacterial cell wall, leading to cell wall instability and bacterial death. It is particularly effective against gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). The term 'empirical' indicates its use as initial broad-spectrum coverage before culture results are available.","oneSentence":"Vancomycin is a glycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:10:44.550Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Empirical treatment of suspected or confirmed gram-positive infections in immunocompromised cancer patients"},{"name":"MRSA infections in cancer patients"}]},"trialDetails":[{"nctId":"NCT04948463","phase":"PHASE4","title":"Early Versus Late Stopping of Antibiotics in Children With Cancer and High-risk Febrile Neutropenia","status":"COMPLETED","sponsor":"Murdoch Childrens Research Institute","startDate":"2021-11-15","conditions":"Febrile Neutropenia","enrollment":55},{"nctId":"NCT06272994","phase":"NA","title":"Swab Testing to Optimize Pneumonia Treatment With Empiric Vancomycin","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2024-04-03","conditions":"Community-acquired Pneumonia","enrollment":277},{"nctId":"NCT07084129","phase":"PHASE1","title":"Vancomycin and Acute Kidney Injury in Sepsis Treatment - Intervention","status":"RECRUITING","sponsor":"Children's Hospital of Philadelphia","startDate":"2026-04","conditions":"Sepsis","enrollment":20},{"nctId":"NCT06970262","phase":"NA","title":"FMT for Lung and Associated-organ Rescue Efficacy in Pulmonary Infection With MDROs","status":"RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2025-05-20","conditions":"Lung Infection, Microbial Colonization, Food Intolerance Syndromes","enrollment":150},{"nctId":"NCT05079620","phase":"PHASE4","title":"Early Antibiotics After Aspiration in ICU Patients","status":"TERMINATED","sponsor":"UConn Health","startDate":"2021-11-30","conditions":"Aspiration, Aspiration Pneumonia","enrollment":5},{"nctId":"NCT05823116","phase":"PHASE4","title":"Continuous vs. Intermittent Infusion Vancomycin","status":"COMPLETED","sponsor":"Aaron Cook","startDate":"2023-05-22","conditions":"Vancomycin","enrollment":37},{"nctId":"NCT07204522","phase":"","title":"Efficacy of Empirical Anti-Infective Therapy in Neutropenic Febrile Patients.","status":"RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-09-22","conditions":"Febrile Neutropenia","enrollment":20},{"nctId":"NCT05975671","phase":"NA","title":"Reducing Empiric VAncomycin Use in Pediatric Suspected Sepsis","status":"RECRUITING","sponsor":"Children's Hospital of Philadelphia","startDate":"2023-08-21","conditions":"Sepsis, Sepsis Mrsa, Sepsis Bacteremia","enrollment":52500},{"nctId":"NCT04983901","phase":"PHASE2","title":"PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-09-14","conditions":"Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm","enrollment":100},{"nctId":"NCT06661772","phase":"","title":"Influencing Factors of Vancomycin Trough Level in Critically Ill Children With Sepsis","status":"COMPLETED","sponsor":"Benha University","startDate":"2024-06-01","conditions":"Critically Ill Children, Sepsis","enrollment":160},{"nctId":"NCT03224052","phase":"","title":"Empirical ANtibiotic THErapy in Adults Hospitalised With Malaria","status":"COMPLETED","sponsor":"Menzies School of Health Research","startDate":"2016-05-01","conditions":"Malaria, Bacteremia, Sepsis","enrollment":20},{"nctId":"NCT05655689","phase":"","title":"The Antibiogram and Outcomes of Antimicrobial Regimens in Microbial Keratitis: A Prospective Cohort Study","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2021-12-31","conditions":"Bacterial Keratitis, Fungal Keratitis, Mixed Bacterial and Fungal Keratitis","enrollment":123},{"nctId":"NCT06161870","phase":"PHASE4","title":"Clinical Study of Individualized Vancomycin Dosing Based on Population PK Model","status":"RECRUITING","sponsor":"Central South University","startDate":"2021-01-01","conditions":"Severe Infection","enrollment":112},{"nctId":"NCT03850860","phase":"","title":"Comparison of Two Empirical Antimicrobial Therapies of Prosthetic Joint Infection","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2018-12-01","conditions":"Bone and Joint Infection","enrollment":178},{"nctId":"NCT01431326","phase":"","title":"Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care","status":"COMPLETED","sponsor":"Daniel Benjamin","startDate":"2011-11","conditions":"Adenovirus, Anesthesia, Anxiety","enrollment":3520},{"nctId":"NCT02660554","phase":"NA","title":"Trial of MRSA Polymerase Chain Reaction for Pneumonia","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2016-01","conditions":"Pneumonia, Methicillin-Resistant Staphylococcus Aureus","enrollment":45},{"nctId":"NCT03586362","phase":"","title":"Vancomycin De-escalation Therapy in Patients With Pneumonia","status":"UNKNOWN","sponsor":"CAMC Health System","startDate":"2018-02-08","conditions":"Pneumonia","enrollment":278},{"nctId":"NCT03485950","phase":"PHASE2","title":"Comparative Study To Determine The Efficacy, Safety, And Tolerability Of Ceftolozane-Tazobactam","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-05-16","conditions":"Other Infectious Diseases","enrollment":100},{"nctId":"NCT03941951","phase":"NA","title":"Study to Optimize the Use of New Antibiotics","status":"UNKNOWN","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2019-07-09","conditions":"Bacterial Infections, Fungal Infection","enrollment":900},{"nctId":"NCT02896218","phase":"","title":"Therapeutic Monitoring of Vancomycin in Critical Ill Patients: a Registry","status":"UNKNOWN","sponsor":"Peking University Third Hospital","startDate":"2016-10","conditions":"Critically Ill","enrollment":400},{"nctId":"NCT03615781","phase":"NA","title":"Two Versus Four Weeks of Antibiotic Treatment in Native Joint Arthritis","status":"COMPLETED","sponsor":"University Hospital, Geneva","startDate":"2015-06-01","conditions":"Arthritis, Septic","enrollment":85},{"nctId":"NCT01570192","phase":"PHASE2","title":"Clinical Trials to Reduce the Risk of Antimicrobial Resistance","status":"TERMINATED","sponsor":"University of Florida","startDate":"2010-09","conditions":"Bacterial Pneumonia","enrollment":43},{"nctId":"NCT00050401","phase":"PHASE3","title":"Ventilator-Associated Pneumonia/Hospital-Acquired Pneumonia Requiring Mechanical Ventilatory Support","status":"COMPLETED","sponsor":"Pfizer","startDate":"2002-07","conditions":"Pneumonia","enrollment":500},{"nctId":"NCT02732327","phase":"PHASE2","title":"Comparative Study of Ceftazidime-Avibactam Versus Standard of Care as Therapy in Febrile Neutropenic Adults With Cancer","status":"TERMINATED","sponsor":"Forest Laboratories","startDate":"2016-05-17","conditions":"Neoplasms, Febrile Neutropenia","enrollment":2},{"nctId":"NCT02463747","phase":"PHASE4","title":"Short vs Prolonged Antibiotic Treatment for Hospitalized Hemato-oncology Patients With Febrile Neutropenia","status":"UNKNOWN","sponsor":"Tel-Aviv Sourasky Medical Center","startDate":"2015-06","conditions":"Fever, Febrile Neutropenia","enrollment":110},{"nctId":"NCT01820026","phase":"PHASE4","title":"Empirical vs 2nd Line Antibiotic Therapy in Health-care Associated Infections in Cirrhosis","status":"UNKNOWN","sponsor":"University of Roma La Sapienza","startDate":"2012-12","conditions":"Cirrhosis","enrollment":96},{"nctId":"NCT02191475","phase":"PHASE2, PHASE3","title":"Effect Study of Tigecycline to Treat Severe Sepsis and Septic Shock","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2014-05","conditions":"Abdominal Infection","enrollment":100},{"nctId":"NCT01867138","phase":"PHASE3","title":"Neonatal Suspected Sepsis Treated With Cefazolin or Vancomycin","status":"COMPLETED","sponsor":"Hospital Italiano de Buenos Aires","startDate":"2007-03","conditions":"Nosocomial Neonatal Sepsis","enrollment":109},{"nctId":"NCT01473979","phase":"NA","title":"Delayed Primary Versus Late Secondary Wound Closure in Sternum Infections","status":"UNKNOWN","sponsor":"University of Lausanne Hospitals","startDate":"2012-01","conditions":"Mediastinitis","enrollment":100},{"nctId":"NCT00035425","phase":"PHASE3","title":"Treatment of Neutropenic Patients With Fever Who Are Suspected to Have A Gram Positive Infection","status":"COMPLETED","sponsor":"Pfizer","startDate":"2001-11","conditions":"Febrile Neutropenia","enrollment":120},{"nctId":"NCT00454272","phase":"PHASE4","title":"Comparison of Teicoplanin and Vancomycin in Initial Empirical Antibiotic Regimen for Febrile Neutropenic Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2005-01","conditions":"Infection, Febrile Neutropenia","enrollment":197},{"nctId":"NCT00138112","phase":"PHASE3","title":"Trial of Prophylactic Versus Empirical Vancomycin for the Prevention of Streptococcal Sepsis After Hematopoietic Cell Transplantation","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2003-11","conditions":"Streptococcal Sepsis, Hematologic Malignancies","enrollment":126}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":60,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Empirical Vancomycin","genericName":"Empirical Vancomycin","companyName":"Memorial Sloan Kettering Cancer Center","companyId":"memorial-sloan-kettering-cancer-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Vancomycin is a glycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors. Used for Empirical treatment of suspected or confirmed gram-positive infections in immunocompromised cancer patients, MRSA infections in cancer patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}